Keensight Capital Acquires Majority Stake in Isto Biologics

Keensight Capital agreed to acquire a majority stake in Isto Biologics from Thompson Street Capital Partners (TSCP). TSCP will retain a minority stake, alongside Isto Biologics’ management team.

Founded in 2016, Isto Biologics is a regenerative medtech company developing and manufacturing orthobiologic products to help patients heal faster. Isto’s product offering covers six functional areas of bone graft solutions, and includes a range of allografts, which are used for bone repair in the spine. Isto sells its products to more than 400 hospitals and clinics, which are used in 15,000 surgical procedures per month, primarily in the United States.

With the support of TSCP, Isto has rapidly grown its product offerings and client base, both organically and through select M&A activity, including the acquisition of Advanced Biologics in 2023.

Keensight will leverage its experience and expertise to further grow Isto into a global leader in biomaterials for tissue regeneration. Through its extensive international network and with the support of the Keensight Performance team, Keensight will contribute to accelerating Isto’s growth strategy, both organically and through acquisitions.

Don Brown, CEO, and Brian Barnes, President of Isto Biologics, said: “Building on our successful collaboration with TSCP, we are looking forward to working with Keensight as we enter the next phase of our growth. Our focus is on helping patients heal faster, and we are excited to bring our solutions to more hospitals and patients. Keensight’s deep sector expertise and global platform will help us to pursue an ambitious strategy to increase our geographical reach and product offerings.”

Source: Keensight Capital